Navigation Links
GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
Date:10/29/2008

gy companies. The ID CEDD currently consists of three discovery units for antivirals, antibacterials and medicines against diseases of the developing world. It focuses on building an innovative pipeline through both internal efforts and external alliances with other companies and research institutions. Its Infectious Diseases Centre of Excellence for External Drug Discovery (ID CEEDD) will focus on 'virtualising' a portion of the infectious diseases pipeline by forming multiple risk-sharing/reward-sharing alliances.

About Genelabs Technologies

Genelabs is a biopharmaceutical company focused on the discovery and development of novel compounds for infectious diseases. In addition to a late- stage drug candidate for hepatitis E partnered with GSK, the company is advancing multiple partnered and proprietary compounds designed to selectively inhibit replication of the hepatitis C virus. For more information, please visit http://www.genelabs.com.

Cowen and Company was the exclusive financial advisor to Genelabs in this transaction.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2007.

Important additional information will be filed with the Securities Exchange Commission (SEC).

This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of Genelabs. The tender offer for shares of Genelabs' stock described in this press release has not yet been comme
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
2. GlaxoSmithKline and Cellzome Announce Major Strategic Alliance
3. GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza(R)
4. GlaxoSmithKline To Post Quarterly US Grants Report
5. GlaxoSmithKline - Q2 Results and Strategy Update - Interview with CEO
6. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
7. CDC Immunization Advisory Committee Recommends Two New Pediatric Vaccines from GlaxoSmithKline
8. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
9. GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
10. GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience
11. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Involution Studios , a ... a new infographic, Understanding Ebola . The ... designed, easy to follow informative tool for anyone wanting ... symptoms and prevention. , "As the news has spread ... Ebola outbreak represents not only a healthcare crisis with ...
(Date:10/22/2014)... October 22, 2014 Physicians Choice ... cardiovascular pharmacogenetics menu, which enables healthcare providers to ... With PCLS’s evidence-based results, healthcare providers are better ... their therapy, while minimizing risks for adverse drug ... according to the FDA [1] more than 2.2 ...
(Date:10/22/2014)... 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) – ... people worldwide are living with diabetes, with  that number ... The global market for diabetes treatments is approximately $500 ... worldwide died from pancreatic cancer.  Pancreatic cancer is the ... in the United States , and ...
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... and the field of polymer science and engineering ... unique properties and processing advantages, which are unattainable ... advances in polymer science and engineering will be ... energy, sustainability, clean water, food preservation, healthcare, informatics, ...
... LAFAYETTE, Ind. ╨ Engineers have discovered details about the behavior ... in manufacturing, diagnostics and other research., ... and surface textures in metals, ceramics and other materials for ... lasers pulse at durations of 100 femtoseconds, or quadrillionths of ...
... Corporation (NYSE: CO ) ("CCBC" or the "Company"), ... China, today announced the results of its 2011 Annual General ... Kong. At the Annual General Meeting, shareholders ... Lu to serve on the Board of Directors until the ...
Cached Biology Technology:Research and education success earns more NSF funding 2Research and education success earns more NSF funding 3Research could improve laser-manufacturing technique 2China Cord Blood Corporation Announces Results of 2011 Annual General Meeting 2
(Date:10/16/2014)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market announces ... the Smart Wallet, at the 13 th annual ... global conference on the intersection of technology and the ... , founder and publisher of the Strategic News Service™, ...
(Date:10/15/2014)... is spreading rapidly and to an unexpected extent. The ... past and the virus shows a new disease dynamic ... For this reason, the German National Academy of Sciences ... Engineering, and the Union of the German Academies of ... Ebola epidemic today. , In the statement the academies ...
(Date:10/14/2014)... cancer tumors scavenge and hoard copper that is an ... be a fatal weakness. , Researchers at Duke ... cells by delivering a trove of copper along with ... with the mineral, leaving non-cancer cells healthy. , The ... for other uses, could soon be tested in clinical ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Prostate cancer's penchant for copper may be a fatal flaw 2
... the National Institutes of Health (NIH) have determined the ... Borrelia burgdorferi , the bacteria that cause Lyme disease. ... how genetic variations among strains may result in different ... most common tickborne disease in North America. The wealth ...
... 2010 - Alcohol is one of the most commonly ... likely to develop alcoholism as women. Until now, the ... remained unclear. A new study published in Biological ... factor. Researchers from Columbia and Yale studied male and ...
... understand the effects of climate change on the microbial ... and the tundra in Alaska, a University of Oklahoma ... of Energy grant. According to Jizhong Zhou, OU ... Institute for Environmental Genomics, the results of these studies ...
Cached Biology News:Why are men more susceptible to alcoholism? 2
...
Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Acetyl CoA Carboxylase Antibody...
mu Opioid Receptor splice variant Immunogen: Synthetic peptide corresponding to residues K S C M D R G M R N L L P D D G P R Q E of Mu Opioid Receptor. Storage: -20 C, Avoid Freeze/Thaw Cycle...
Biology Products: